Record Volumes, Margin Collapse—the ₹6,700 Crore Question
TMPV delivered 34% revenue growth but posted a ₹5.5K crore net loss after an exceptional charge. Underlying profit margin collapsed to 1.1%, and management cut FY27 guidance from implicit 5%+ to explicit 2–3%. The bull case (EV ramp, cost cuts) is real—but recovery is now contingent on unconfirmed commodity easing and JLR stabilization.
₹96,920 Cr
+34% YoY; volume +29%
-₹5,451 Cr
After ₹6,700 Cr exceptional
1.1%
PBT ₹400 Cr pre-exceptional
2–3%
Cut from implicit 5%+
On the surface, it's a blowout: TMPV grew revenue 34% and held market leadership at 14.3%, with EV volumes nearly doubling. But the ₹5,451 crore net loss masks what management delivered—and what they conceded. Strip out the ₹6,700 crore JLR restructuring charge (voluntary redundancy and asset writedowns), and the company still posted a 1.1% EBIT margin, well below the profitability tone implied in prior guidance. That margin collapse, combined with a full-year guidance cut to the 2–3% EBIT range (from an implicit 5%+ prior), is the real quarter.
The ₹6,700 crore charge: What it hides
JLR's restructuring (₹295 crore voluntary redundancy, ₹530 crore asset writedowns) is real and necessary—the division has been loss-making—but it also masks organic weakness. Underlying EBIT was only 1.1% (₹400 Cr PBT) before the exceptional, against a backdrop of claimed commodity offset success. The company said it would offset 40% of commodity inflation via pricing and cost actions year-to-date; delivered was negative operating margin of −1.9%, suggesting the offset fell short. Price increases of 1.9% YTD lagged cost inflation, and the exceptional charge masks the fact that core profitability was already under pressure.
Claims on the call vs. what holds up
Revenue ₹96,920 Cr, up 34% YoY
India volumes 67,000 units/month, up 40% YoY
EV volumes doubled YoY, 43% market share
EBIT margin 1.1%, PBT ₹400 Cr pre-exceptional
Commodity offset 40% via price + cost (claim)
Four out of five claims hold up. The fifth—the commodity offset—is contradicted by the numbers. Despite management's assertion that calibrated pricing and cost actions offset 40% of cost inflation year-to-date, the delivered result was negative operating margin (−1.9%). Price increases fell short; cost actions did not fully compensate. This is the credibility gap of the quarter.
What changed on this call
FY27 EBIT guidance cut to 2–3% from an implicit 5%+. Prior calls implied margin recovery was underway; the company now explicitly guides to a narrower range, citing commodity persistence through Q3, JLR headwinds, and China market contraction (wholesale down 45% YoY). Margin recovery deferred to H2 FY27, contingent on commodity easing (potential, not confirmed) and JLR launches (Type 01, Range Rover BEV, not yet revenue-accretive). China strategy underspecified: Balaji's lengthy China defense but no concrete plan to reverse the 45% YoY wholesale decline; Chery partnership not yet ramping. Cost savings target raised: ₹1.7B cost reduction program and ₹400 crore annual headcount reduction, signaling management is serious—but execution timing unclear amid capex peak.
Risks, ranked by how much they should concern a holder
Margin recovery execution
HIGHFY27 EBIT guidance (2–3%) is now explicit and narrow. Recovery depends on commodity easing (potential in Q4, not confirmed) and JLR stabilization (launches not yet accretive). If either slips, guidance credibility collapses.
JLR profitability crisis
HIGH₹6,700 Cr restructuring charge masks ongoing operating losses. New launches (Type 01, Range Rover BEV) ramp-up uncertain; cyber incident in prior quarter. Cash drain continues.
Commodity volatility persists
HIGHCompany expects elevated commodity costs through Q3, with easing potential only in Q4. If inflation proves sticky, pricing power is capped by demand elasticity; cost actions may not keep pace.
China market structural decline
HIGHChina wholesale down 45% YoY; market size down 30% overall. Local Chinese OEMs gaining share. JLR exposed; Chery partnership not yet ramping. No imminent recovery visible.
EV supply chain tightness
MEDIUMEV demand (16,000 units/month, 90% growth) outpaces capacity. Argesta (sister company cell producer) ramp timing critical. If supply disrupted, revenue upside capped.
How the street is positioned
The market verdict on the print is clear: the stock fell 8.7% on day 1 and was down 12.13% by day 3, confirming the fundamental weakness. FII stakes have eroded: 15.32% now, down 1.79 percentage points QoQ from 17.11%. DII flat (17.92%, up 0.69pp). The stock sits at ₹263.5, 62.66% below its all-time high and trading below its 20-day, 50-day, and 200-day moving averages. At just 4.58% above its 52-week low, the stock reflects both the guidance cut and the market's loss of confidence in near-term execution. The absence of institutional buying into the dip is telling.
What to watch next
1 · Q3 FY27 — JLR launches and commodity curve
Range Rover BEV and Type 01 Jaguar launches begin; commodity prices stabilize (expected but unconfirmed). If launches drive revenue and OPM recovers to 2–3% range, credibility rebuilds. If not, margin miss compounds.
2 · H2 FY27 — Cost savings realization and Aeris ramp
Aeris demand is ahead of capacity; scaling production while cost actions mature (₹400 crore headcount reduction, ₹1.7B ex-works program) is the execution test. Cash flow turns positive if working capital and capex discipline hold.
3 · China trajectory and FY28 guidance
By year-end, it will be clear whether China volume stabilizes or continues to erode, and whether JLR launches show traction. FY28 guidance (targeting double-digit EBITDA and return to net cash by FY30) will reset market expectations.
TMPV delivered record growth—but at negative margin. The company reset guidance to 2–3% EBIT, acknowledging that commodity offset fell short and JLR restructuring deferred profitability. The street has exited (FII -1.79pp); the stock is 62% off its high. The long-term story (EV scale, cost savings, market leadership) is intact—but near-term execution risk is too high to chase now. Hold pending margin recovery proof in H2 FY27. The number to track: FY27 EBIT margin. If it misses the 2–3% guidance, downside accelerates.
Informational and educational content only. Not investment advice.